Literature DB >> 12006617

Distinct effects of thrombopoietin depending on a threshold level of activated Mpl in BaF-3 cells.

Gaël A Millot1, William Vainchenker, Dominique Duménil, Fédor Svinarchuk.   

Abstract

Thrombopoietin (TPO) plays a critical role in megakaryopoiesis through binding to its receptor Mpl. This involves activation of various intracellular signaling pathways, including phosphoinositide 3-kinase (PI3K) and the mitogen-activated protein kinase (MAPK) pathways. Their precise role in TPO-mediated proliferation, survival and differentiation is not fully understood. In the present study, we show that TPO induces different biological responses in Mpl-transduced BaF-3 cells, depending on the cell surface density of Mpl and the resulting activation level of signaling pathways. TPO mediates cell proliferation in cells expressing high levels of Mpl but only mediates survival without proliferation in cells expressing low levels of the receptor. By using the kinase inhibitors PD98059 and LY294002, we further showed that the activation level of the PI3K and MAPK p42/44 pathways is a determining factor for the proliferative effect. In cells expressing low levels of Mpl, the survival effect was strongly dependent on the activation level of the PI3K/AKT, but not the MAPK p42/44 pathway. Moreover, this effect was correlated with the phosphorylation level of BAD but not with the expression level of Bcl-X(L). However, PI3K pathway inhibition did not increase apoptosis when BaF-3 cells proliferated in response to TPO, indicating a compensating mechanism from other Mpl signaling pathways in this case.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006617     DOI: 10.1242/jcs.115.11.2329

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  6 in total

1.  TNF-alpha sensitizes normal and fibrotic human lung fibroblasts to Fas-induced apoptosis.

Authors:  Stephen K Frankel; Gregory P Cosgrove; Seung-Ick Cha; Carlyne D Cool; Murry W Wynes; Benjamin L Edelman; Kevin K Brown; David W H Riches
Journal:  Am J Respir Cell Mol Biol       Date:  2005-11-04       Impact factor: 6.914

2.  Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes.

Authors:  Zhi-Jian Liu; Joseph Italiano; Francisca Ferrer-Marin; Ravi Gutti; Matthew Bailey; Brandon Poterjoy; Lisa Rimsza; Martha Sola-Visner
Journal:  Blood       Date:  2011-02-08       Impact factor: 22.113

3.  YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation.

Authors:  Ian S Hitchcock; Maximus M Chen; Jennifer R King; Kenneth Kaushansky
Journal:  Blood       Date:  2008-05-16       Impact factor: 22.113

4.  Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders.

Authors:  Sigal Gery; Saskia Gueller; Katya Chumakova; Norihiko Kawamata; Liqin Liu; H Phillip Koeffler
Journal:  Blood       Date:  2007-08-10       Impact factor: 22.113

5.  Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors.

Authors:  Lu Cui; Ignacio Moraga; Tristan Lerbs; Camille Van Neste; Stephan Wilmes; Naotaka Tsutsumi; Aaron Claudius Trotman-Grant; Milica Gakovic; Sarah Andrews; Jason Gotlib; Spyros Darmanis; Martin Enge; Stephen Quake; Ian S Hitchcock; Jacob Piehler; K Christopher Garcia; Gerlinde Wernig
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-12       Impact factor: 11.205

6.  c-Mpl-del, a c-Mpl alternative splicing isoform, promotes AMKL progression and chemoresistance.

Authors:  Fei Li; Yuanyan Xiong; Mo Yang; Peiling Chen; Jingkai Zhang; Qiong Wang; Miao Xu; Yiming Wang; Zuyong He; Xin Zhao; Junyu Huang; Xiaoqiong Gu; Li Zhang; Rui Sun; Xunsha Sun; Jingyao Li; Jinxin Ou; Ting Xu; Xueying Huang; Yange Cao; Xiaohong Ruby Xu; Danielle Karakas; June Li; Heyu Ni; Qing Zhang
Journal:  Cell Death Dis       Date:  2022-10-13       Impact factor: 9.685

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.